New Risk • May 15
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • May 07
Full year 2026 earnings released: EPS: ₹17.40 (vs ₹15.01 in FY 2025) Full year 2026 results: EPS: ₹17.40 (up from ₹15.01 in FY 2025). Revenue: ₹4.16b (up 21% from FY 2025). Net income: ₹775.1m (up 16% from FY 2025). Profit margin: 19% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 07
Vimta Labs Limited announces Annual dividend, payable on July 08, 2026 Vimta Labs Limited announced Annual dividend of INR 2.0000 per share payable on July 08, 2026, ex-date on June 18, 2026 and record date on June 18, 2026. Announcement • May 06
Vimta Labs Limited, Annual General Meeting, Jun 25, 2026 Vimta Labs Limited, Annual General Meeting, Jun 25, 2026. New Risk • Apr 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Jan 29
Third quarter 2026 earnings released: EPS: ₹3.96 (vs ₹3.93 in 3Q 2025) Third quarter 2026 results: EPS: ₹3.96 (up from ₹3.93 in 3Q 2025). Revenue: ₹1.00b (up 12% from 3Q 2025). Net income: ₹175.9m (flat on 3Q 2025). Profit margin: 18% (down from 20% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Jan 07
Now 21% overvalued Over the last 90 days, the stock has fallen 14% to ₹618. The fair value is estimated to be ₹510, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%. Buy Or Sell Opportunity • Dec 22
Now 20% overvalued Over the last 90 days, the stock has fallen 18% to ₹619. The fair value is estimated to be ₹515, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%. Buy Or Sell Opportunity • Nov 25
Now 20% overvalued Over the last 90 days, the stock has fallen 2.6% to ₹615. The fair value is estimated to be ₹512, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 16%. Reported Earnings • Nov 04
Second quarter 2026 earnings released: EPS: ₹4.46 (vs ₹3.84 in 2Q 2025) Second quarter 2026 results: EPS: ₹4.46 (up from ₹3.84 in 2Q 2025). Revenue: ₹1.05b (up 23% from 2Q 2025). Net income: ₹199.2m (up 17% from 2Q 2025). Profit margin: 19% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹764, the stock trades at a trailing P/E ratio of 47.3x. Average trailing P/E is 41x in the Life Sciences industry in India. Total returns to shareholders of 333% over the past three years. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹659, the stock trades at a trailing P/E ratio of 40.7x. Average trailing P/E is 53x in the Life Sciences industry in India. Total returns to shareholders of 229% over the past three years. Reported Earnings • Jul 18
First quarter 2026 earnings released: EPS: ₹4.25 (vs ₹2.77 in 1Q 2025) First quarter 2026 results: EPS: ₹4.25 (up from ₹2.77 in 1Q 2025). Revenue: ₹993.1m (up 22% from 1Q 2025). Net income: ₹188.9m (up 54% from 1Q 2025). Profit margin: 19% (up from 15% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jun 12
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Jun 07
Vimta Labs Limited Approves Dividend for the Financial Year Ended March 31, 2025 Vimta Labs Limited announced at annual general meeting held on June 6, 2025, the shareholders approved to declare a dividend of INR 2 per equity share for the financial year ended March 31, 2025. Upcoming Dividend • May 23
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 30 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 6.7% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.4%). Announcement • May 16
Vimta Labs Limited, Annual General Meeting, Jun 06, 2025 Vimta Labs Limited, Annual General Meeting, Jun 06, 2025, at 10:00 Indian Standard Time. Reported Earnings • May 16
Full year 2025 earnings released: EPS: ₹30.28 (vs ₹18.51 in FY 2024) Full year 2025 results: EPS: ₹30.28 (up from ₹18.51 in FY 2024). Revenue: ₹3.48b (up 9.1% from FY 2024). Net income: ₹667.6m (up 63% from FY 2024). Profit margin: 19% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 24
Vimta Labs Limited to Report Q4, 2025 Results on Apr 28, 2025 Vimta Labs Limited announced that they will report Q4, 2025 results on Apr 28, 2025 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹853, the stock trades at a trailing P/E ratio of 34.7x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 128% over the past three years. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹1,003, the stock trades at a trailing P/E ratio of 40.6x. Average trailing P/E is 48x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹947, the stock trades at a trailing P/E ratio of 38.6x. Average trailing P/E is 50x in the Life Sciences industry in India. Total returns to shareholders of 197% over the past three years. Recent Insider Transactions • Feb 19
Key Executive recently sold ₹3.1m worth of stock On the 12th of February, V. Vungal sold around 3k shares on-market at roughly ₹1,084 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. V. has been a net seller over the last 12 months, reducing personal holdings by ₹4.2m. Recent Insider Transactions • Feb 14
Key Executive recently sold ₹1.0m worth of stock On the 6th of February, V. Vungal sold around 975 shares on-market at roughly ₹1,038 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹5.8m. This was V.'s only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹1,043, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 164% over the past three years. Reported Earnings • Jan 25
Third quarter 2025 earnings released: EPS: ₹7.86 (vs ₹4.57 in 3Q 2024) Third quarter 2025 results: EPS: ₹7.86 (up from ₹4.57 in 3Q 2024). Revenue: ₹911.5m (up 12% from 3Q 2024). Net income: ₹175.2m (up 73% from 3Q 2024). Profit margin: 19% (up from 12% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 24
Vimta Labs Limited Appoints Siva Rama Krishna Kambhampati as Chief Financial Officer, Effective 3 March, 2025 Vimta Labs Limited announced that at the board meeting held on January 24, 2025 approved the appointment of Shri. Siva Rama Krishna Kambhampati as Chief Financial Officer of the Company with effect from 3 March, 2025. Shri. Siva Rama Krishna Kambhampati is a seasoned finance professional with experience in Strategic Financial planning, controlling, costing, treasury management and designing internal controls. Experienced in working with cross functional and cross-cultural teams. He has an overall experience of 15 years and has worked with various listed and unlisted companies. Announcement • Jan 20
Vimta Labs Limited to Report Q3, 2025 Results on Jan 24, 2025 Vimta Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025 Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹825, the stock trades at a trailing P/E ratio of 37.2x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 95% over the past three years. New Risk • Jan 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risk Significant insider selling over the past 3 months (₹21m sold). Announcement • Dec 04
Vimta Labs Limited Announces Resignation of Rama Narahai Naidu Dodda as Chief Financial Officer, Effective 10 December 2024 Vimta Labs Limited announced that Shri. Rama Narahai Naidu Dodda, Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), has resigned from the services of the Company, with effect from close of business hours on 10 December 2024, as he wants to pursue career opportunities outside Vimta Labs Limited. Recent Insider Transactions • Dec 03
Insider recently sold ₹5.8m worth of stock On the 25th of November, Vasireddi Prasad sold around 7k shares on-market at roughly ₹828 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹26m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹897, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 142% over the past three years. New Risk • Nov 21
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹9.8m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.6% average weekly change). Significant insider selling over the past 3 months (₹9.8m sold). Recent Insider Transactions • Nov 21
Insider recently sold ₹3.8m worth of stock On the 14th of November, Vasireddi Prasad sold around 5k shares on-market at roughly ₹759 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹19m more than they bought in the last 12 months. Reported Earnings • Nov 09
Second quarter 2025 earnings released: EPS: ₹7.68 (vs ₹2.85 in 2Q 2024) Second quarter 2025 results: EPS: ₹7.68 (up from ₹2.85 in 2Q 2024). Revenue: ₹854.3m (up 16% from 2Q 2024). Net income: ₹170.2m (up 169% from 2Q 2024). Profit margin: 20% (up from 8.6% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Nov 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change). Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹694, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 49x in the Life Sciences industry in India. Total returns to shareholders of 98% over the past three years. Announcement • Nov 05
Vimta Labs Limited to Report Q2, 2025 Results on Nov 08, 2024 Vimta Labs Limited announced that they will report Q2, 2025 results on Nov 08, 2024 Announcement • Oct 11
Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million. Thyrocare Technologies Limited (BSE:539871) entered into Business Transfer Agreement to acquire Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on August 30, 2024. A cash consideration of INR 70 million will be paid by Thyrocare Technologies Limited. For the period ended March 31, 2024 Diagnostics and and pathological services business of Virnta Labs Limited had revenue of INR 296.67 million.
Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million on October 11, 2024. New Risk • Sep 19
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: ₹4.9m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Significant insider selling over the past 3 months (₹4.9m sold). Valuation Update With 7 Day Price Move • Aug 28
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹608, the stock trades at a trailing P/E ratio of 32.8x. Average trailing P/E is 46x in the Life Sciences industry in India. Total returns to shareholders of 112% over the past three years. Announcement • Jul 18
Vimta Labs Limited Approves Dividend for the Year Ended March 31, 2024 Vimta Labs Limited announced that at its AGM held on July 18, 2024, shareholders approved the dividend of INR 2 per equity shares for the financial year ended March 31, 2024. Announcement • Jul 12
Vimta Labs Limited to Report Q1, 2025 Results on Jul 17, 2024 Vimta Labs Limited announced that they will report Q1, 2025 results on Jul 17, 2024 Upcoming Dividend • Jul 04
Upcoming dividend of ₹2.00 per share Eligible shareholders must have bought the stock before 11 July 2024. Payment date: 25 July 2024. Payout ratio is a comfortable 11% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (0.6%). Recent Insider Transactions • Jun 28
Insider recently sold ₹3.5m worth of stock On the 21st of June, Vasireddi Prasad sold around 7k shares on-market at roughly ₹493 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹35m more than they bought in the last 12 months. Reported Earnings • Jun 26
Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023) Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.19b (flat on FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 23
Vimta Labs Limited, Annual General Meeting, Jul 18, 2024 Vimta Labs Limited, Annual General Meeting, Jul 18, 2024, at 10:00 Indian Standard Time. Reported Earnings • May 19
Full year 2024 earnings released: EPS: ₹18.51 (vs ₹21.77 in FY 2023) Full year 2024 results: EPS: ₹18.51 (down from ₹21.77 in FY 2023). Revenue: ₹3.22b (up 1.0% from FY 2023). Net income: ₹410.1m (down 15% from FY 2023). Profit margin: 13% (down from 15% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹560, the stock trades at a trailing P/E ratio of 30x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 125% over the past three years. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹434, the stock trades at a trailing P/E ratio of 23.2x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 163% over the past three years. Recent Insider Transactions • Feb 28
President recently sold ₹982k worth of stock On the 23rd of February, Suresh Kumar sold around 2k shares on-market at roughly ₹491 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Suresh's only on-market trade for the last 12 months. Reported Earnings • Feb 01
Third quarter 2024 earnings released: EPS: ₹4.57 (vs ₹4.62 in 3Q 2023) Third quarter 2024 results: EPS: ₹4.57 (down from ₹4.62 in 3Q 2023). Revenue: ₹825.7m (up 6.7% from 3Q 2023). Net income: ₹101.3m (down 1.1% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 20
Vimta Labs Limited to Report Q3, 2024 Results on Jan 31, 2024 Vimta Labs Limited announced that they will report Q3, 2024 results on Jan 31, 2024 Reported Earnings • Nov 01
Second quarter 2024 earnings released: EPS: ₹2.85 (vs ₹5.97 in 2Q 2023) Second quarter 2024 results: EPS: ₹2.85 (down from ₹5.97 in 2Q 2023). Revenue: ₹754.5m (down 5.5% from 2Q 2023). Net income: ₹63.3m (down 52% from 2Q 2023). Profit margin: 8.4% (down from 17% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹497, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 23x in the Life Sciences industry in India. Total returns to shareholders of 279% over the past three years. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹581, the stock trades at a trailing P/E ratio of 26.6x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 444% over the past three years. Recent Insider Transactions • Aug 13
Insider recently sold ₹4.9m worth of stock On the 10th of August, Praveena Vasireddi sold around 10k shares on-market at roughly ₹490 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹24m more than they bought in the last 12 months. Reported Earnings • Jul 29
First quarter 2024 earnings released: EPS: ₹5.51 (vs ₹5.45 in 1Q 2023) First quarter 2024 results: EPS: ₹5.51 (up from ₹5.45 in 1Q 2023). Revenue: ₹840.7m (up 6.2% from 1Q 2023). Net income: ₹122.0m (up 1.3% from 1Q 2023). Profit margin: 14% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹471, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 31x in the Life Sciences industry in India. Total returns to shareholders of 420% over the past three years. Announcement • Jun 29
Vimta Labs Limited Declares Dividend for the Financial Year Ended March 31, 2023 Vimta Labs Limited at its 33rd Annual General Meeting held on 28 June 2023, declared a dividend of INR 2 per equity share for the financial year ended March 31, 2023. Upcoming Dividend • Jun 14
Upcoming dividend of ₹2.00 per share at 0.5% yield Eligible shareholders must have bought the stock before 21 June 2023. Payment date: 07 July 2023. Payout ratio is a comfortable 9.2% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Reported Earnings • May 05
Full year 2023 earnings released: EPS: ₹21.77 (vs ₹18.70 in FY 2022) Full year 2023 results: EPS: ₹21.77 (up from ₹18.70 in FY 2022). Revenue: ₹3.22b (up 15% from FY 2022). Net income: ₹481.7m (up 17% from FY 2022). Profit margin: 15% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹337, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 198% over the past three years. Reported Earnings • Jan 30
Third quarter 2023 earnings released: EPS: ₹4.62 (vs ₹5.28 in 3Q 2022) Third quarter 2023 results: EPS: ₹4.62 (down from ₹5.28 in 3Q 2022). Revenue: ₹773.8m (up 15% from 3Q 2022). Net income: ₹102.4m (down 12% from 3Q 2022). Profit margin: 13% (down from 17% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Nov 26
President recently sold ₹2.3m worth of stock On the 21st of November, Suresh Kumar sold around 5k shares on-market at roughly ₹463 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹16m. This was Suresh's only on-market trade for the last 12 months. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improved over the past week After last week's 18% share price gain to ₹481, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 35x in the Life Sciences industry in India. Total returns to shareholders of 397% over the past three years. Recent Insider Transactions • Nov 05
Insider recently sold ₹16m worth of stock On the 2nd of November, Rajya Vasireddi sold around 40k shares on-market at roughly ₹408 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Board Change • Aug 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 3 highly experienced directors. Additional Non-Executive Independent Director Yadagiri Pendri was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 26
First quarter 2023 earnings released: EPS: ₹5.45 (vs ₹3.65 in 1Q 2022) First quarter 2023 results: EPS: ₹5.45 (up from ₹3.65 in 1Q 2022). Revenue: ₹800.2m (up 30% from 1Q 2022). Net income: ₹120.4m (up 49% from 1Q 2022). Profit margin: 15% (up from 13% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year. Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment improved over the past week After last week's 16% share price gain to ₹372, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 114% over the past three years.